Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study - Jänne, P A; Shaw, A T; Pereira, J R (Lancet Oncol, 2013)
, et al.